We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $588M
1-Year Est. Return 182.75%
This Fund
S&P 500
This Quarter Est. Return
+77.63%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$581M
AUM Growth
+$190M
Cap. Flow
+$101M
Cap. Flow %
17.32%
Top 10 Hldgs %
39.55%
Holding
201
New
71
Increased
49
Reduced
24
Closed
56

Top Buys

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$13.1M
2
CORT icon
Corcept Therapeutics
CORT
+$7.65M
3
VKTX icon
Viking Therapeutics
VKTX
+$5.07M
4
UTHR icon
United Therapeutics
UTHR
+$4.66M
5
BBIO icon
BridgeBio Pharma
BBIO
+$4.59M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$13.5M
2
PCVX icon
Vaxcyte
PCVX
+$8.74M
3
SLNO
Soleno Therapeutics
SLNO
+$8.25M
4
INDV icon
Indivior Pharmaceuticals
INDV
+$7.23M
5
BMY icon
Bristol-Myers Squibb
BMY
+$5.86M

Sector Composition

Rank Sector Weight
1 Healthcare 28.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NKTR icon
176
Nektar Therapeutics
NKTR
$2.38B
– –
-75,000
Closed -$4.27M
NVAX icon
177
CALL
Novavax
NVAX
$1.22B
– –
-173,500
Closed -$1.5M
NVO
178
Novo Nordisk
NVO
$208B
– –
-25,000
Closed -$1.28M
OVID icon
179
Ovid Therapeutics
OVID
$435M
– –
-187,739
Closed -$244K
PMVP icon
180
PMV Pharmaceuticals
PMVP
$59.7M
– –
-11,300
Closed -$15.8K
PYXS icon
181
Pyxis Oncology
PYXS
$193M
– –
-150,000
Closed -$333K
RARE icon
182
Ultragenyx Pharmaceutical
RARE
$2.46B
– –
-9,189
Closed -$302K
RARE icon
183
PUT
Ultragenyx Pharmaceutical
RARE
$2.46B
– –
-123,300
Closed -$3.71M
RCEL icon
184
CALL
Avita Medical
RCEL
$142M
– –
-25,100
Closed -$128K
REPL icon
185
CALL
Replimune Group
REPL
$1B
– –
-612,300
Closed -$2.57M
RLAY icon
186
Relay Therapeutics
RLAY
$4.09B
– –
-43,616
Closed -$228K
RNAM
187
DELISTED
Avidity Biosciences
RNAM
– –
-30,000
Closed -$1.94M
ROIV icon
188
Roivant Sciences
ROIV
$24.1B
– –
-120,000
Closed -$2.37M
RVPH
189
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
– –
-125,346
Closed -$1.39M
SCPH
190
CALL
DELISTED
scPharmaceuticals
SCPH
– –
-462,000
Closed -$2.62M
SLNO
191
PUT
DELISTED
Soleno Therapeutics
SLNO
– –
-100,000
Closed -$6.76M
SMMT icon
192
CALL
Summit Therapeutics
SMMT
$10.4B
– –
-74,700
Closed -$1.54M
SPY icon
193
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$806B
– –
-20,000
Closed -$13.3M
SRRK icon
194
CALL
Scholar Rock
SRRK
$5.49B
– –
-100,000
Closed -$3.72M
SUPN icon
195
Supernus Pharmaceuticals
SUPN
$2.67B
– –
-22,348
Closed -$1.07M
TNYA icon
196
Tenaya Therapeutics
TNYA
$158M
– –
-315,519
Closed -$511K
SKYE icon
197
CALL
Skye Bioscience
SKYE
$20.5M
– –
-300,000
Closed -$1.18M
MBX
198
CALL
MBX Biosciences
MBX
$3.07B
– –
-100,000
Closed -$1.75M
CLYM
199
Climb Bio
CLYM
$676M
– –
-136,488
Closed -$274K
UPB
200
CALL
Upstream Bio Inc
UPB
$349M
– –
-200,000
Closed -$3.76M
5 6 7
8
9

Similar funds

MC
Martin & Co Knoxville, Tennessee $587M AUM 16.39% 1-Year Est. Return
PFG
Premier Financial Group Eureka, California $587M AUM 21.88% 1-Year Est. Return
FMI
Frec Markets Inc San Francisco, California $587M AUM
EGWAG
Elwood & Goetz Wealth Advisory Group Athens, Georgia $589M AUM 19.26% 1-Year Est. Return
PFG
PAX Financial Group San Antonio, Texas $586M AUM 15.84% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $586M AUM 15.35% 1-Year Est. Return
FL
Fourthstone LLC St Louis, Missouri $590M AUM 29.58% 1-Year Est. Return
BA
Bellwether Advisors Lincoln, Nebraska $590M AUM 35.66% 1-Year Est. Return

Diadema Partners's Q4 2025 Portfolio in Review

As of Q4 2025, Diadema Partners held 201 positions worth $581M, up 48% from $391M the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Diadema Partners deployed $101M of net new capital in Q4 2025, opening 71 new positions and adding to 49 existing holdings. Its largest new stake was Johnson & Johnson: 66,444 shares worth $13.8M.

By sector, the portfolio is most concentrated in Healthcare at 29% of assets, down from 37% a quarter earlier.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $13.5M trimmed.

  • Diadema Partners's largest Q4 2025 buy was Johnson & Johnson: 66,444 shares worth $13.8M.
  • Diadema Partners added most to Viking Therapeutics in Q4 2025, an estimated $5.07M increase.
  • Diadema Partners's biggest Q4 2025 reduction was Regeneron Pharmaceuticals, cutting an estimated $13.5M.
  • Diadema Partners fully exited Bristol-Myers Squibb in Q4 2025, selling an estimated $5.86M.
  • Diadema Partners's ten largest holdings make up 40% of its $581M portfolio in Q4 2025.
  • Diadema Partners opened 71 new positions and closed 56 in Q4 2025.
  • Diadema Partners's portfolio value rose 48% quarter-over-quarter to $581M.

Based on Diadema Partners's 13F filing for Q4 2025, filed 17 Feb 2026.